Posters & Abstracts Author Reference
Pooled data analysis of the safety and tolerability of intravenous Pelareorep in combination with chemotherapy in 500 + cancer patients Gutierrez et al ESMO September 2017
Mechanism of Pelareorep (Pel)-mediated cell death in a Phase I study in combination with irinotecan/ fluorouracil/ leucovorin/ bevacizumab (FOLFIRI/B) in patients with KRAS mutant metastatic colorectal cancer (mCRC) Goel et al ESMO September 2017
A study of REOLYSIN® in combination with Pembrolizumab and chemotherapy in patients (pts) with relapsed metastatic adenocarcinoma of the pancreas (MAP). Mahalingam et al ASCO 2017
A randomized (RCT) phase II study of oncolytic reovirus (pelareorep) plus standard weekly paclitaxel (P) as therapy for metastatic breast cancer (mBC). Bernstein et al ASCR April 2017
Oncolytic Virus Therapy in Pancreatic Cancer: Clinical Efficacy and Pharmacodynamic Analysis of REOLYSIN® in Combination with Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma. Mahalingam et al EMSO July 2015
PDL-1 blockade and Sunitinib enhance the efficiency of oncolytic viral therapy. Mostafa et al AACR 2014
Combination therapy with reovirus and PD-1 blockade effectively establishes tumor control via innate and adaptive immune responses. Rajani et al Mayo Foundation 2014
Combination therapy with reovirus and immunomodulatory drugs induces direct oncolytic and immune-mediated killing of multiple myeloma cells and overcomes stromal-mediated microenvironmental protection. Parrish et al ASH 2014
Presentations Author Reference
REOLYSIN® and Immune Therapy: Rationale for Combination Therapy Dr. Matt Coffey
REOLYSIN® and Immune Checkpoint Inhibitors: Rationale for Combination Therapy Dr. Giovanni Selvaggi
Clinical Virotherapy and Immune Modulation – Bench to Bedside and Back Again Dr. Alan Melcher
Publications Author Reference
MOA - Tumor Lysis
Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors Villalona-Calero, M.A., et al. Cancer, 2016. 122(6): p. 875-83
The combination of intravenous REOLYSIN® and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer Mahalingam et al BMC Cancer (2015) 15:513
Reovirus oncolysis of human breast cancer Norman, K.L., et al Hum Gene Ther, 2002. 13(5): p. 641-52
REOLYSIN® is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer Carew, J.S., et al Cell Death Dis, 2013. 4: p. e728
Oncolytic viral therapy for human pancreatic cancer cells by reovirus Etoh, T., et al Clin Cancer Res, 2003. 9(3): p. 1218-23
Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells Sei, S., et al Mol Cancer, 2009. 8: p. 47
Intravenous administration of REOLYSIN®, a live replication competent RNA virus is safe in patients with advanced solid tumors Gollamudi, R., et al Invest New Drugs, 2010. 28(5): p. 641-9
MOA - Immunity
Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients Adair, R.A., et al Sci Transl Med, 2012. 4(138): p. 138ra77
Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells Adair, R.A., et al Int J Cancer, 2013. 132(10): p. 2327-38
Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo El-Sherbiny, Y.M., et al Clin Exp Immunol, 2015. 180(1): p. 98-107
Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity Errington, F., et al The Journal of Immunology, 2008. 180(9): p. 6018-6026
Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity Gujar, S.A., et al Mol Cancer Ther, 2010. 9(11): p. 2924-33
Oncolytic virus-initiated protective immunity against prostate cancer Gujar, S.A., et al Mol Ther, 2011. 19(4): p. 797-804
Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication Prestwich, R.J., et al Clin Cancer Res, 2009. 15(13): p. 4374-81
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses Rajani, K., et al Mol Ther, 2016. 24(1): p. 166-74
Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial White, C.L., et al Gene Ther, 2008. 15(12): p. 911-20
Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-kappaB mediated and supports innate and adaptive anti-tumor immune priming Steele, L., et al Mol Cancer, 2011. 10: p. 20